Vabysmo (faricimab-svoa) is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor. It is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. This therapeutic agent is used to manage retinal conditions where vascular instability and increased permeability are present.
How VABYSMO Works
Faricimab is a humanized bispecific antibody that functions by binding to and inhibiting both VEGF-A and Ang-2. By blocking VEGF-A, the drug suppresses the proliferation of endothelial cells, the formation of new blood vessels, and vascular leakage. Inhibition of Ang-2 is thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. These dual pathways address the increased levels of Ang-2 found in patients with certain macular and retinal vascular diseases.
What is Vabysmo?
Vabysmo (faricimab-svoa) is sold under an FDA application first approved in January 2022, held by Roche. It acts on Ang-2 and VEGFA.
How much does Vabysmo sell?
Roche reported $5.3 billion of Vabysmo sales in the four quarters from Q4 2025 to Q3 2026, $1.4 billion of it in Q3 2026. Roche reports in Swiss francs; these are dollar conversions at its quarterly rates. Source: Roche's Q3 2026 report.
What competes with Vabysmo?
Other companies' marketed drugs that act on the same target include Eylea and Beovu.
From FDA's approval records, the company's own quarterly report (linked above where shown) and TheraRadar's curated drug targets.
Details
- Status
- Prescription
- First Approved
- 2022-01-28
- Patent Cliff
- 2034
- Revenue
- $1.4B (Q3-2026) converted from CHF 1,137m
- Routes
- INTRAVITREAL
- Dosage Forms
- INJECTABLE
VABYSMO Approval History
What VABYSMO Treats
3 indicationsVABYSMO is approved for 3 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Neovascular Age-Related Macular Degeneration
- Diabetic Macular Edema
- Macular Edema Following Retinal Vein Occlusion
VABYSMO Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to VABYSMO
3 of 10FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Roche's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VABYSMO FDA Label Details
Indications & Usage
FDA Label (PDF)VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with: VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD) Diabetic Macular Edema (DME) Macular Edema Following Retinal Vein Occlusion (RVO) 1.1 Neovascular (wet) Age-Related Macular Degeneration (nAMD) 1.2 Diabetic Macular Edema (DME) 1.3 Macular Edema Following Retinal Vein Occlusion (RVO)
Pro Intelligence Preview
Deep insights for VABYSMO
Revenue Insights
- • Q3-2026: $1.4B (converted from CHF 1,137m)
- • Historical trend analysis
Patent Timeline
- • Cliff: 2034
- • Generic/biosimilar risk
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 10 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.